BioTuesdays

Tag - Kumaraguru Raja

Cyclacel Pharmaceuticals

Brookline starts Cyclacel Pharma at buy; PT $22

Brookline Capital Markets initiated coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $22 price target. The stock closed at $4.12 on May 18. Cyclacel is developing small molecule drugs targeting...

Edesa Biotech

Brookline starts Edesa Biotech at buy; PT $10

Brookline Capital Markets launched coverage of Edesa Biotech (NASDAQ:EDSA) with a “buy” rating and $10 price target. The stock closed at $2.16 on March 27. Edesa is developing EB01, a topical sPLA2 inhibitor that...

Hepion Pharmaceuticals

Brookline starts Hepion Pharma at buy; PT $12

Brookline Capital Markets launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $12 price target. The stock closed at $3.39 on Nov. 21. Hepion is developing CRV431, a novel pleiotropic...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.